Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cuprina Holdings (Cayman) Limited Class A ( (CUPR) ) has issued an announcement.
On June 4, 2025, Cuprina Holdings announced the completion of a laboratory in Saudi Arabia, through its associate Cuprina MENA Co. Ltd, to manufacture and supply MEDIFLY maggot debridement therapy across the MENA region. Additionally, Cuprina MENA secured exclusive rights to market medicinal leeches in the GCC countries, expanding their market reach and potential revenue. These developments are expected to enhance Cuprina’s industry positioning in the MENA and GCC regions.
More about Cuprina Holdings (Cayman) Limited Class A
Cuprina Holdings (Cayman) Limited is a Singapore-based biomedical and biotechnology company focused on developing and commercializing products for chronic wound management and infertility, as well as cosmeceuticals for the health and beauty sector.
Average Trading Volume: 197,633
For a thorough assessment of CUPR stock, go to TipRanks’ Stock Analysis page.